A small Connecticut biotech throws hat into IPO ring
A biotech looking to treat skin diseases sent in word to the SEC that it wants to go public.
Azitra joins a relatively small group of biotechs seeking an IPO in the past few quarters, with only a handful going public in recent memory, including two on back-to-back Fridays this month.
The biotech’s lead program is ATR-12, with a Phase Ib to start in the first half of this year for Netherton syndrome, a rare autosomal disease that is marked by inflammation, scaling, and red and dehydrated skin that’s caused by mutations in the SPINK5 gene. The company says there are about 20,000 patients worldwide with the disease and sees a $250 million peak sales opportunity. The trial is expected to read out in the first half of next year. The FDA has assigned it pediatric rare disease designation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.